Approval · Notice of Compliance 28503 · 2022
MAR-RANITIDINE: Notice of Compliance 28503
Issued June 29, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28503
- Date
- June 29, 2022
- Company
- Marcan Pharmaceuticals Inc.Ottawa, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Extension of shelf-life. Label revisions
- Canadian reference product
- ZANTAC (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MAR-RANITIDINE | Not yet assigned | — |
Medicinal ingredients
- RANITIDINE HCL 150 MG per TAB
- RANITIDINE HCL 300 MG per TAB